Lapatinib
| CAS No. | 231277-92-2 | Cat. No. | BCP01874 |
| Name | Lapatinib | ||
| Synonyms | GSK572016; GSK-572016; GSK 572016; GW2016; GW-2016; GW 2016; | ||
| Formula | C29H26ClFN4O4S | M. Wt | 581.06 |
| Description | Lapatinib weakly inhibits the activity of ErbB4 with IC50 of 367 nM, and displays >300-fold selectivity for EGFR and ErbB2 over other kinases such as c-Src, c-Raf, MEK, ERK, c-Fms, CDK1, CDK2, p38, Tie-2, and VEGFR2. Lapatinib significantly inhibits receptor autophosphorylation of EGFR and ErbB2 in a dose-dependent manner with IC50 of 170 nM and 80 nM, respectively in HN5 cells; as well as 210 nM and 60 nM, respectively in BT474 cells. Unlike OSI-774 and Iressa (ZD1839) which preferentially inhibit the growth of the EGFR-overexpressing cells, Lapatinib inhibits the growth of both EGFR- and ErbB2-overexpressing cells. | ||
| Related Products | 388082-78-8（Lapatinib Ditosylate） 388082-77-7（Lapatinib ditosylate） | ||
| Pathways | Angiogenesis/Protein Tyrosine Kinase Jak/Stat Pathway | ||
| Targets | EGFR HER2 | ||
|
Molecular regulation of apoptotic machinery and lipid metabolism by mTORC1/mTORC2 dual inhibitors in preclinical models of HER2+/PIK3CAmut breast cancer
Publications Citing of Biochempartner's Lapatinib(CAS:231277-92-2) |
|
mTOR complex-2 stimulates acetyl-CoA and de novo lipogenesis through ATP citrate lyase in HER2/PIK3CA-hyperactive breast cancer
Publications Citing of Biochempartner's Lapatinib(CAS:231277-92-2) |
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.